Management in Intensive Care Unit of Life-threatening Keto-Acidosis (MILKA)
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Analysis of patients with International Statistical Classification of Diseases and Related Health Problems coding compatible with inclusion
- Selection of patients eligible for inclusion based on review of medical records (verification of inclusion and non-inclusion criteria)
- Telephone contact and sending of the information letter on participation in the study and research of the patient's non-opposition to his participation and the processing of his data.
- Collection of retrospective data
- Phone call to collect prospective data
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: ROUX Damien, Dr
- Phone Number: 0147606194
- Email: damien.roux@aphp.fr
Study Contact Backup
- Name: VERNEY Charles, Pr
- Phone Number: 0147606713
- Email: charles.verney@aphp.fr
Study Locations
-
-
-
Bobigny, France, 93000
- Avicenne
-
Colombes, France, 92700
- Louis Mourier
-
Le Kremlin-Bicêtre, France, 94270
- BICETRE
-
Paris, France, 75012
- Saint-Louis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Major (age ≥ 18 years old)
- Hospitalized in intensive care between January 2014 and December 2023 for ketoacidosis complicated by organ failure in the participating departments.
- Diagnosis of ketoacidosis judged to be the main cause of the severity of the clinical condition.
- Blood potential hydrogen < 7.15 and bicarbonates < 10mmol/L in the first 12 hours of treatment.
- Presenting at least one of the 3 organ failures during hospitalization among:
- Use of extra-renal purification for acute renal failure
- Administration of pressor amines
- Use of mechanical ventilation
Exclusion Criteria:
- Metabolic acidosis primarily of an origin other than ketonic
- Refusal to participate or opposition to the processing of their data
- Patient under guardianship or curators
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluate the incidence of mortality in intensive care units of patients hospitalized for severe diabetic ketoacidosis.
Time Frame: up to 6 months
|
Percentage of mortality in intensive care units in patients admitted for ketoacidosis complicated by organ failure.
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-A00455-38
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ketoacidosis
-
NCT06838507Not yet recruitingSGLT2 Inhibitor | Ketoacidosis, Eugylcemic
-
NCT06399510RecruitingTreatment Diabetic Ketoacidosis, Electrolyte Balance Effects
-
NCT02763423Unknown
-
NCT06877975Recruiting
-
NCT02994316CompletedDiabetic Ketoacidosis Children
-
NCT05808972CompletedMetabolic Ketoacidosis | Ketoacidemia | Acetonemia | Acetonuria
-
NCT03066440TerminatedDiabetic Ketoacidosis
-
NCT00589680Completed